Alto Neuroscience, Inc. (NYSE:ANRO) Stake Increased by Barclays PLC

Barclays PLC increased its stake in Alto Neuroscience, Inc. (NYSE:ANRO) by 34.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,807 shares of the company’s stock after buying an additional 10,208 shares during the period. Barclays PLC’s holdings in Alto Neuroscience were worth $168,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ANRO. Wells Fargo & Company MN increased its stake in Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after purchasing an additional 3,139 shares during the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in Alto Neuroscience during the fourth quarter valued at $74,000. Rhumbline Advisers increased its stake in Alto Neuroscience by 24.4% during the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after purchasing an additional 5,008 shares during the last quarter. Jane Street Group LLC bought a new stake in Alto Neuroscience during the third quarter valued at $124,000. Finally, Bank of New York Mellon Corp increased its stake in Alto Neuroscience by 15.0% during the fourth quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company’s stock valued at $221,000 after purchasing an additional 6,812 shares during the last quarter.

Analyst Ratings Changes

Several analysts have weighed in on the stock. HC Wainwright assumed coverage on shares of Alto Neuroscience in a research note on Monday, April 7th. They set a “buy” rating and a $10.00 target price for the company. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.40.

Alto Neuroscience Stock Performance

Shares of ANRO opened at $2.36 on Wednesday. Alto Neuroscience, Inc. has a 1 year low of $1.60 and a 1 year high of $17.55. The company has a market cap of $63.89 million, a price-to-earnings ratio of -0.93 and a beta of 1.87. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The firm has a fifty day moving average of $2.43 and a 200-day moving average of $3.46.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.09. As a group, equities analysts anticipate that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.